These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 23802629)

  • 1. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
    Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication.
    Orlandi C; Canovari B; Bozzano F; Marras F; Pasquini Z; Barchiesi F; De Maria A; Magnani M; Casabianca A
    J Transl Med; 2020 May; 18(1):204. PubMed ID: 32429953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells.
    Badralmaa Y; Natarajan V
    J Virol Methods; 2013 Oct; 193(1):184-9. PubMed ID: 23773807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of 2-LTR circle junctions of viral DNA in infected cells.
    Mandal D; Prasad VR
    Methods Mol Biol; 2009; 485():73-85. PubMed ID: 19020819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring HIV-1 Nuclear Import Kinetics Using a Chemically Induced Nuclear Pore Blockade Assay.
    Dharan A; Campbell EM
    Methods Mol Biol; 2024; 2807():141-151. PubMed ID: 38743226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-long terminal repeat (LTR) DNA circles are a substrate for HIV-1 integrase.
    Richetta C; Thierry S; Thierry E; Lesbats P; Lapaillerie D; Munir S; Subra F; Leh H; Deprez E; Parissi V; Delelis O
    J Biol Chem; 2019 May; 294(20):8286-8295. PubMed ID: 30971426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
    Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
    Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
    Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
    J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
    Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
    J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
    Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F;
    AIDS; 2010 Sep; 24(15):2391-5. PubMed ID: 20683319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
    Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
    J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.
    Zhu W; Jiao Y; Lei R; Hua W; Wang R; Ji Y; Liu Z; Wei F; Zhang T; Shi X; Wu H; Zhang L
    PLoS One; 2011; 6(6):e21081. PubMed ID: 21687638
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.